Eupraxia Pharmaceuticals Inc. Stock Analysis & AI Score
Eupraxia Pharmaceuticals Inc. (EPRX) has an ST Score of 55.1 (B-), driven by its Financial Strength (A) and held back by its Growth (F). Analysts rate it Buy with a $19.67 price target (+141.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Eupraxia Pharmaceuticals Inc. (EPRX) has an ST Score of 55.1 (B-), driven by its Financial Strength (A) and held back by its Growth (F). Analysts rate it Buy with a $19.67 price target (+141.1% upside).
- Strongest
- Financial StrengthA
- Weakest
- GrowthF
All factor grades
- Financial StrengthA
- ForecastA
- MomentumA-
- ValuationB-
- ProfitabilityB-
- GrowthF
- Piotroski2/9
Contact
EPRX stock: frequently asked questions
What is EPRX's ST Score?
Eupraxia Pharmaceuticals Inc. (EPRX) has an ST Score of 55.1 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is EPRX a buy, hold, or sell?
Analysts rate EPRX a Buy, with a price target of $19.67 (+141.1% vs the current price). Our ST Score grades it B- (55.1/100). The ST Score is a data-driven signal, not a recommendation.
What are EPRX's factor grades?
Valuation B-, Profitability B-, Financial Strength A, Momentum A-, Growth F, Forecast A.
What is EPRX's valuation grade?
Eupraxia Pharmaceuticals Inc. (EPRX) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is EPRX's growth grade?
Eupraxia Pharmaceuticals Inc. (EPRX) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is EPRX's profitability grade?
Eupraxia Pharmaceuticals Inc. (EPRX) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is EPRX's financial strength grade?
Eupraxia Pharmaceuticals Inc. (EPRX) earns a financial strength grade of A, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for EPRX?
The average analyst price target for Eupraxia Pharmaceuticals Inc. (EPRX) is $19.67 from 2 analysts, which is +141.1% versus the recent price of $8.16.
What is EPRX's Piotroski score?
Eupraxia Pharmaceuticals Inc. (EPRX) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.